Featured Research Search Results

Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back

Clinicaltrials.gov identifier:
NCT06888921

Treatment
Study for relapsed platinum-sensitive ovarian cancer

A New Drug, DT2216, Combined With Paclitaxel for Recurrent Platinum-Resistant Ovarian Cancer

Clinicaltrials.gov identifier:
NCT06964009

Treatment
Phase 1b study for people with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer

Clinicaltrials.gov identifier:
NCT07318363

Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

Clinicaltrials.gov identifier:
NCT06974110

Treatment
Treatment study for people with advanced or metastatic cancers

Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study

Clinicaltrials.gov identifier:
NCT06995898

Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer

A 5-minute Patient and Caregiver survey to share experiences with immunotherapy and any short-term or long-term side effects

Surveys, Registries, Interviews
This 5-minute survey allows cancer patients on immunotherapy (currently or in the past) and their caregivers to share their experiences, including their side effects and whether they were resolved or not.

Testing the Drug CX-5461 for Treating Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT06606990

Treatment
Phase 1 study for treatment of advanced solid tumors

Testing a Targeted Therapy ETX-19477 to Treat Advanced Solid Tumors in People with a BRCA2 Mutation (ERADIC8)

Clinicaltrials.gov identifier:
NCT06395519

Treatment
Phase 1/2 treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

Clinicaltrials.gov identifier:
NCT07218809

Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

Clinicaltrials.gov identifier:
NCT05059444

Treatment
Post-treatment study to monitor for recurrence

An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)

Clinicaltrials.gov identifier:
NCT05463796

Prevention
Study for people at risk of cancer, including previvors, survivors and family members

The EASE Study: Helping People with Advanced Cancer Cope with Fear of Cancer Progression

Clinicaltrials.gov identifier:
NCT07636200

Quality of Life
Quality of life study for people with advanced cancer experiencing anxiety

A Study of Fallopian Tube Removal with Delayed Ovary Removal to Lower Ovarian Cancer Risk (TUBA-WISP-II)

Clinicaltrials.gov identifier:
NCT04294927

Prevention
Prevention study for women at high risk for ovarian cancer

Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

Clinicaltrials.gov identifier:
NCT05372640

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

Clinicaltrials.gov identifier:
NCT06580314

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations

Clinicaltrials.gov identifier:
NCT04890613

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs

Clinicaltrials.gov identifier:
NCT06167317

Treatment
Treatment study for people with advanced or metastatic solid tumors